Journals / Türk Biyokimya Dergisi / 2019 / Cilt: 44 - Sayı: 1

Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line

Ginnalin A ve SB203580 Hep-3B hepatosellüler karsinoma hücre hattında additif etki gösterir

Pages
78–85
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This study indicates that GA and SB203580 can be an effective for development of new therapeutic strategies in hepatocellular carcinoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Investigation of the anticarcinogenic effects of natural products with low toxicity is very important in the development of new therapeutic strategies against cancer.
📊
Key Findings & Data:SB203580, a p38 MAPK inhibitor, can inhibit cell proliferation independently of p38 MAPK.
💡
Conclusion & Impact:Conclusion: This study indicates that GA and SB203580 can be an effective for development of new therapeutic strategies in hepatocellular carcinoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Investigation of the anticarcinogenic effects of natural products with low toxicity is very important in the development of new therapeutic strategies against cancer. Ginnalin A (GA) is one of the most important phenolic compounds of Acer genus and its anticancer effect has been shown that in various cancer cell lines. SB203580, a p38 MAPK inhibitor, can inhibit cell proliferation independently of p38 MAPK. The objective of this study was to investigate combination effect of GA and SB203580 on Hep-3B cell line. Material and methods: Cell viability was determined by using XTT method after the treatment with GA, SB203580 and combination of both. Anticarcinogenic effects of GA and SB203580 both in single and in combination have been analyzed with Caspase-3 activity assay and expression levels of important genes involved in cell cycle and apoptosis were evaluated by qPCR. Results: GA and SB203580 have shown additive effect on Hep-3B cells in the combination inhibited 50% of cell viability. And, SB203580 increased the effect of GA on activation of Caspase-3 and expressions of genes important in apoptosis and cell cycle. Conclusion: This study indicates that GA and SB203580 can be an effective for development of new therapeutic strategies in hepatocellular carcinoma.

Özet

Amaç: Düşük toksisiteli doğal ürünlerin antikarsinojenik etkilerinin araştırılması, kansere karşı yeni tedavi stratejilerinin geliştirilmesinde oldukça önemlidir. Ginnalin A (GA), Acer cinsinin en önemli fenolik bileşiklerinden biridir ve çeşitli kanser hücre hatlarında antikanser etkisi gösterilmiştir. Bir p38 MAPK inhibitörü olan SB203580, p38 MAPK’den bağımsız olarak hücre proliferasyonunu inhibe edebilmektedir. Bu çalışmanın amacı, GA ve SB203580’in Hep-3B hücre hattında kombinasyon etkisinin araştırılmasıdır. Yöntem: GA, SB203580 ve her ikisinin kombinasyonu ile muameleden sonra hücre canlılığı XTT yöntemi kullanılarak belirlenmiştir. GA ve SB203580’in hem tek başına hem de kombine olarak antikarsinojenik etkileri Kaspaz-3 aktivite testi ile analiz edilmiş ve hücre döngüsü ile apoptozda önemli genlerin ekspresyon seviyeleri qPCR ile değerlendirilmiştir. Bulgular: GA ve SB203580, Hep-3B hücreleri üzerinde hücre canlılığının %50’sini inhibe ettikleri kombinasyonda additif etki göstermiştir. Ayrıca, SB203580 GA’nın Kaspaz-3 aktivasyonu ve apoptoz ile hücre döngüsünde önemli olan genlerin ifadeleri üzerindeki etkisini arttırmıştır. Sonuç: Bu çalışma, GA ve SB203580’in hepatosellüler karsinomada yeni terapötik stratejilerin geliştirilmesinde etkili olabileceğini göstermektedir.

🔖

Cite This Article

özden, P., VURAL, H., AVCI, E. (2022). Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. Türk Biyokimya Dergisi, Cilt: 44 - Sayı: 1, 78–85. https://ajindex.com/articles/620917

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Tam K. The roles of doxorubicin in hepatocellular carcinoma. ADMET & DMPK 2003;1:29–44
  2. Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region. Gut Liver 2016;10:332–9
  3. Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J, et al. Risk factors of hepatocellular carcinoma—current status and perspectives. Asian Pac J Cancer Prev 2012;13:743–52
  4. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1
  5. Chen C. Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. Gut 2018;67:595–8
  6. Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 2017;24:1073274817729245
  7. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115–27
  8. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore) 2017;96:e5904
  9. Gwiasda J, Schulte A, Kaltenborn A, Ramackers W, Kleine M, Beetz O, et al. Identification of the resection severity index as a significant independent prognostic factor for early mortality and observed survival >5 and >10 years after liver resection for hepatocellular carcinoma. Surg Oncol 2017;26:178–87
  10. Deng G, Zeng S, Ma J, Zhang Y, Qu Y, Han Y, et al. The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma. Sci Rep 2017;7:41616
  11. Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol 2017;9:907–20
  12. Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol 2018;48:103–14
  13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90
  14. Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett 2016;371:171–81
  15. Cai Y, Luo Q, Sun M, Corke H. Antioxidant activity and phenolic comp